Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Amortization of Deferred Charges (2019 - 2021)

Historic Amortization of Deferred Charges for Usana Health Sciences (USNA) over the last 3 years, with Q4 2021 value amounting to $2.2 million.

  • Usana Health Sciences' Amortization of Deferred Charges rose 550.85% to $2.2 million in Q4 2021 from the same period last year, while for Oct 2021 it was $9.1 million, marking a year-over-year increase of 477.57%. This contributed to the annual value of $8.8 million for FY2021, which is 602.61% up from last year.
  • Per Usana Health Sciences' latest filing, its Amortization of Deferred Charges stood at $2.2 million for Q4 2021, which was up 550.85% from $2.3 million recorded in Q3 2021.
  • Usana Health Sciences' Amortization of Deferred Charges' 5-year high stood at $2.3 million during Q1 2021, with a 5-year trough of $2.0 million in Q2 2019.
  • In the last 3 years, Usana Health Sciences' Amortization of Deferred Charges had a median value of $2.2 million in 2019 and averaged $2.2 million.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 1146.81% in 2020, then rose by 17.74% in 2021.
  • Quarter analysis of 3 years shows Usana Health Sciences' Amortization of Deferred Charges stood at $2.2 million in 2019, then dropped by 2.07% to $2.1 million in 2020, then rose by 5.51% to $2.2 million in 2021.
  • Its last three reported values are $2.2 million in Q4 2021, $2.3 million for Q3 2021, and $2.3 million during Q2 2021.